Cargando…

CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030589/
http://dx.doi.org/10.1038/gim.2012.62
_version_ 1782317410463776768
collection PubMed
description
format Online
Article
Text
id pubmed-4030589
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40305892014-05-27 CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal) Genet Med Corrigendum Nature Publishing Group 2012-08 2012-08-03 /pmc/articles/PMC4030589/ http://dx.doi.org/10.1038/gim.2012.62 Text en Copyright © 2012 American College of Medical Genetics and Genomics
spellingShingle Corrigendum
CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
title CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
title_full CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
title_fullStr CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
title_full_unstemmed CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
title_short CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
title_sort corrigendum: clinical observation of patients with fabry disease after switching from agalsidase beta (fabrazyme) to agalsidase alfa (replagal)
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030589/
http://dx.doi.org/10.1038/gim.2012.62